A vismodegib regimen that includes a weekend drug holiday showed similar responses to treatment for patients with advanced basal cell carcinoma and basal cell nevus syndrome and provided a more tolerable adverse effect profile.
Although there are a number of treatments for Merkel cell carcinoma, none offers impressive results. Research directed toward finding predictive markers for response, and adjuvant therapies, are warranted.
The geriatric population has unique dermatologic needs and concerns, which differ greatly from those of younger patients, study research finds.
BRAF V600E mutation may indicate a reduced risk for relapse and/or metastasis in patients with melanoma.
There is a decreased risk for melanoma diagnosis among bereaved individuals but increased mortality associated with melanoma compared with nonbereaved individuals.
Despite increases in most sun protective behaviors, the rates of primary and secondary skin preventive behaviors remain suboptimal, and the prevalence of multiple sunburns is rising.
The FDA has accepted for filing the New Drug Application for tirbanibulin ointment (formerly known as KX2-391 or KX-01 ointment; Athenex) for the treatment of actinic keratosis (AK).
Physicians may be reassured, when prescribing methotrexate to their patients with psoriasis, as no association between methotrexate exposure and risk for cutaneous malignant melanoma was noted in a sizeable study.
The percentage of cases of cutaneous melanoma and age-standardized incidence rates attributable to ultraviolet radiation vary across states.
The researchers found that compared with heterosexual men, gay and bisexual men had significantly higher adjusted odds ratios of skin cancer prevalence.
